Friday, December 15, 2017 11:07:43 AM
Hahah. Akika to pass the hat. I love it. hahahahahahahahaha
Cowboy doesn’t want me posting my numbers so I won't (until EOD), but I will be salty if DCTH doesn’t drop the news by EOY. This baby wants to run so badly. But, if you look at the chart, at least we’re chewing up shares and heading north incrementally. The dates of dreaming about being able to jump in at $.03 are over.
In fact, the idea I even have to type the price $.03, $.05 or even $.75 offends my sensibilities. This stock should have a number IN FRONT of the decimal, not just behind it. In the days and weeks ahead, I believe that it will.
So here is some total conjecture and should probably be spit back as nonsense, but indulge me:
Much has been written about the tax benefits for a company by acquiring DTCH. Given it’s been widely acknowledged for months the Trump administration is going to whack corporate tax rates from 35% to 20% or 21% effective beginning tax year 2018, would an acquiring company find any benefit in executing a buyout of DCTH on or before 31 December 2017 to avail themselves of beneficial breaks for 2017 by virtue of acquiring DCTH?
Complete speculation on my part made even worse by the fact I have no idea how corporate taxes are structured in the first place.
Lastly, I will again email DCTH IR and beseech them for an update about the interim safety analysis report. Regardless, my prediction for the date the interim safety analysis report remains: 20 December 2017.
Off to see Star Wars. I'll be back for what I am going to call now, a very nice power half-hour! With that report ready to drop any day now, even I might grab a little more before Monday.
Cowboy doesn’t want me posting my numbers so I won't (until EOD), but I will be salty if DCTH doesn’t drop the news by EOY. This baby wants to run so badly. But, if you look at the chart, at least we’re chewing up shares and heading north incrementally. The dates of dreaming about being able to jump in at $.03 are over.
In fact, the idea I even have to type the price $.03, $.05 or even $.75 offends my sensibilities. This stock should have a number IN FRONT of the decimal, not just behind it. In the days and weeks ahead, I believe that it will.
So here is some total conjecture and should probably be spit back as nonsense, but indulge me:
Much has been written about the tax benefits for a company by acquiring DTCH. Given it’s been widely acknowledged for months the Trump administration is going to whack corporate tax rates from 35% to 20% or 21% effective beginning tax year 2018, would an acquiring company find any benefit in executing a buyout of DCTH on or before 31 December 2017 to avail themselves of beneficial breaks for 2017 by virtue of acquiring DCTH?
Complete speculation on my part made even worse by the fact I have no idea how corporate taxes are structured in the first place.
Lastly, I will again email DCTH IR and beseech them for an update about the interim safety analysis report. Regardless, my prediction for the date the interim safety analysis report remains: 20 December 2017.
Off to see Star Wars. I'll be back for what I am going to call now, a very nice power half-hour! With that report ready to drop any day now, even I might grab a little more before Monday.
Recent DCTH News
- Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts • Business Wire • 05/26/2026 08:01:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
